Table 3

Survival analysis

Local failure-free survivalDisease-free survivalOverall survival
RRCIa (95%) P RRCIa (95%) P RRCIa (95%) P
Univariate analysis
 Age (yr), <57/≥571.130.62–2.080.691.060.60–1.880.840.890.52–1.500.65
 T stage, T1–41.781.10–2.880.021.901.19–3.020.0071.791.22–2.630.003
 N stage, N0–30.990.74–1.330.961.000.76–1.310.981.230.96–1.580.11
 Grade, G1–31.310.79–2.160.301.430.90–2.340.121.070.69–1.660.76
 Smoking, no vs. yes2.830.87–9.180.082.420.87–6.760.093.201.15–8.920.03
 Chemotherapy, no vs. yes0.890.45–1.770.740.770.39–1.510.441.140.63–2.050.66
 HIF-1α, 0–II2.151.24–3.740.0062.011.20–3.370.0082.171.34–3.510.002
  HIF-1α I, focal vs. diffuse1.120.37–3.360.841.170.44–3.150.751.340.53–3.400.54
  HIF-1α II, focal vs. diffuse1.560.64–3.800.321.370.58–3.210.471.120.53–2.360.78
 IMD, I–IVb1.901.34–2.580.00021.711.25–2.320.00071.541.15–2.050.003
Multivariate analysis
 T stage, T1–41.721.10–2.780.031.831.15–2.900.011.691.13–2.530.01
 Smoking, no vs. yes≥0.1≥0.13.561.08–11.740.04
 HIF-1α, 0–II2.431.37–4.300.0022.201.29–3.740.0042.351.42–3.900.0009
 IMD, I–IV2.001.40–2.850.00011.791.28–2.500.00061.651.19–2.290.003
  • a CI, confidence interval.

  • b Data pertaining to IMD are adopted from Aebersold et al. (21) .